Patents by Inventor Judah Folkman

Judah Folkman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6908910
    Abstract: The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosage sufficient to inhibit cell mitosis. The application discloses novel compounds used in the methods.
    Type: Grant
    Filed: February 15, 2002
    Date of Patent: June 21, 2005
    Assignee: The Children's Medical Center Corporation
    Inventors: Robert John D'Amato, Moses Judah Folkman
  • Publication number: 20040229945
    Abstract: The present invention relates to conjugates of water-soluble polymers and o-(chloracetyl-carbamoyl) fumagillol (TNP-470) and use of those conjugates as specific intracellular carriers of the TNP-470 into tumor vessels. The present invention further relates to use of those conjugates to lower the neurotoxicity of TNP-470. Preferably, the polymer has a molecular weight in the range of 100 Da to 800 kDa. More preferably, the polymer has a molecular weight no greater than 60 kDa. Most preferably, the polymer has a molecular weight in the range of 15 kDa to 40 kDa.
    Type: Application
    Filed: February 19, 2004
    Publication date: November 18, 2004
    Applicant: Children's Medical Center Corporation
    Inventors: Ronit Satchi-Fainaro, Judah Folkman
  • Publication number: 20040224877
    Abstract: We have now discovered that partially deglycosylated vitamin D binding protein (DBP-maf) is anti-tumorigenic not wholly via an immune mechanism but in part via an antiangiogenic mechanism. Accordingly, the present invention relates to use of DBP-maf in the treatment of diseases associated with increased or abnormal angiogenesis and/or endothelial cell differentiation. Preferably, the DBP-maf is administered to the patient by sustained release or in pulses. Pulse therapy is not a form of discontinuous administration of the same account of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses.
    Type: Application
    Filed: June 13, 2003
    Publication date: November 11, 2004
    Inventors: Steven Pirie-Shepherd, Oliver Kisker, Shinya Onizuka, Rahul Ray, Swamy Narasimha, M. Judah Folkman
  • Publication number: 20040220249
    Abstract: The present invention provides a method for the minimization or prevention of adhesion formation during or following a surgical procedure. The method comprises administering to the patient in need thereof a therapeutically effective amount of at least one COX-2 inhibitor, wherein the COX-2 inhibitor is not nimesulide. The COX-2 inhibitor can be administered before, during, or after surgery. In a preferred embodiment, the COX-2 inhibitor is celecoxib, also known as Celebrex (Pfizer).
    Type: Application
    Filed: January 29, 2004
    Publication date: November 4, 2004
    Applicant: Children's Medical Center Corporation
    Inventors: Mark Puder, Arin K. Greene, Judah Folkman
  • Publication number: 20040214807
    Abstract: A method of inhibiting neovascularization in a mammal comprises administering to the mammal a neovascularization-inhibiting amount of a compound of the formula disclosed.
    Type: Application
    Filed: February 27, 2004
    Publication date: October 28, 2004
    Inventors: Robert J. D'Amato, M. Judah Folkman
  • Patent number: 6764995
    Abstract: The present invention provides anti-angiogenic compositions, and more particularly provides endostatin protein fragments. The compositions of the present invention may be used for the treatment of angiogenesis-dependent diseases such as cancer.
    Type: Grant
    Filed: September 23, 1999
    Date of Patent: July 20, 2004
    Assignee: The Children's Medical Center Corporation
    Inventors: Michael S. O'Reilly, M. Judah Folkman
  • Patent number: 6746865
    Abstract: Nucleic acid sequences encoding for endostatin protein. Ribonucleic and deoxyribonucleic acid sequences that encode for endostatin protein are useful for gene therapy or recombinant expression for the treatment of angiogenesis-related diseases, specifically angiogenesis-dependent cancer.
    Type: Grant
    Filed: October 16, 1998
    Date of Patent: June 8, 2004
    Assignee: The Children's Medical Center Corporation
    Inventors: Michael S. O′Reilly, M. Judah Folkman
  • Publication number: 20040102372
    Abstract: An inhibitor of endothelial cell proliferation, capable of inhibiting angiogenesis and causing tumor regression, that is approximately 20 kDa and corresponds to a C-terminal fragment of collagen type XVIII, and methods of treating angiogenesis-related disease.
    Type: Application
    Filed: February 4, 2003
    Publication date: May 27, 2004
    Inventors: Michael S. O'Reilly, M. Judah Folkman
  • Patent number: 6740678
    Abstract: The present invention provides a method for treating cardiovascular ailments. The method involves first screening an individual to determine their risk of having the potential for unstable plaques. Such individuals can be selected by looking at one of the following criteria: (i) increased plaque neovascularization, (ii) area ratio of intima to wall area of a plaque, (iii) evidence of plaque hemorrhage, or (iv) inflammatory cells associated with plaque vessels. Looking at these criteria permits one to select individuals having the potential for unstable plaques. The method then involves treating the selected individual with an effective amount of an angiogenesis inhibitor.
    Type: Grant
    Filed: March 30, 2001
    Date of Patent: May 25, 2004
    Assignee: Children's Medical Center Corporation
    Inventors: Karen S. Moulton, Judah Folkman
  • Patent number: 6723858
    Abstract: The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosage sufficient to inhibit cell mitosis. The application discloses novel compounds used in the methods.
    Type: Grant
    Filed: February 21, 2002
    Date of Patent: April 20, 2004
    Assignee: The Children's Medical Center Corporation
    Inventors: Robert John D'Amato, Moses Judah Folkman
  • Publication number: 20040072813
    Abstract: The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosage sufficient to inhibit cell mitosis. The application discloses novel compounds used in the methods.
    Type: Application
    Filed: July 10, 2003
    Publication date: April 15, 2004
    Inventors: Robert John D'Amato, Moses Judah Folkman
  • Publication number: 20040023877
    Abstract: The present invention provides plasminogen fragments containing kringle region domains having anti-angiogenic activity and terned angiostatin protein. The plasminogen fragments of the present invention may be used for the treatment of angiogenesis-dependent diseases such as cancer.
    Type: Application
    Filed: March 27, 2003
    Publication date: February 5, 2004
    Inventors: Michael S. O'Reilly, M. Judah Folkman, Yihai Cao
  • Publication number: 20040002459
    Abstract: Fragments of an endothelial cell proliferation inhibitor and method of use therefor are provided. The endothelial proliferation inhibitor is a protein derived from plasminogen, or more specifically is an angiostatin fragment. The angiostatin fragments generally correspond to kringle structures occurring within the endothelial cell proliferation inhibitor. The endothelial cell inhibiting activity of these fragments provides a means for inhibiting angiogenesis of tumors and for treating angiogenic-mediated disease.
    Type: Application
    Filed: March 28, 2003
    Publication date: January 1, 2004
    Inventors: M. Judah Folkman, Michael S. O'Reilly
  • Publication number: 20030236408
    Abstract: The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosage sufficient to inhibit cell mitosis. The application discloses novel compounds used in the methods.
    Type: Application
    Filed: February 12, 2001
    Publication date: December 25, 2003
    Inventors: Robert John D'Amato, Moses Judah Folkman
  • Publication number: 20030219426
    Abstract: An inhibitor of endothelial cell proliferation, capable of inhibiting angiogenesis and causing tumor regression, that is approximately 20 kDa and corresponds to a C-terminal fragment of collagen type XVIII, and methods of treating angiogenesis-related disease.
    Type: Application
    Filed: January 24, 2003
    Publication date: November 27, 2003
    Inventors: Michael S. O'Reilly, M. Judah Folkman
  • Publication number: 20030203838
    Abstract: The invention provides for methods of reducing or inhibiting angiogenesis, tumor growth and endothelial cell proliferation by the administration of compositions containing fragments, conformations, biological equivalent, or derivatives of antithrombin III. The invention also provides for pharmaceutical compositions comprising a fragment, conformation, biological equivalent, or derivative of antithrombin III and methods of identifying novel inhibitors of tumor growth, endothelial cell proliferation, and/or angiogenesis. The invention also relates to compositions and methods for altering angiogenesis in a mammal, as well as to methods of treatment for disorders associated with angiogenesis (e.g., cancer).
    Type: Application
    Filed: June 13, 2003
    Publication date: October 30, 2003
    Inventors: Michael S. O'Reilly, M. Judah Folkman, Steven Pirie-Shepherd
  • Patent number: 6638949
    Abstract: A method and compositions for inhibiting excessive scar formation and adhesions by administering to a patient in need thereof an effective amount of an angiogenesis inhibitor. In the preferred embodiment, the angiogenesis inhibitor is selective, such as a fumagillol derivative like 0-chloroacetylcarbamoyl-Fumagillol (TNP-470, TAP Pharmaceuticals), thalidomide, or a selective drug having more than one activity, such as minocycline or penicilliamine which also have antibiotic activity. Less selective compounds can also be used, such as the cytokine IL12. Patients to be treated include those having experienced trauma, surgical intervention, burns, and other types of injuries. The inhibitor is administered in an amount effective to decrease excessive scarring, defined as formation of high density tissue including cells and connective tissue, without preventing normal wound closure. The inhibitors can be administered systemically and/or locally or topically, as needed.
    Type: Grant
    Filed: August 25, 1998
    Date of Patent: October 28, 2003
    Inventors: Judah Folkman, Harold Brem, H. Paul Ehrlich
  • Publication number: 20030195180
    Abstract: The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosage sufficient to inhibit cell mitosis. The application discloses novel compounds used in the methods.
    Type: Application
    Filed: March 3, 2003
    Publication date: October 16, 2003
    Inventors: Robert John D'Amato, Moses Judah Folkman
  • Patent number: 6630448
    Abstract: Methods of inhibiting angiogenesis by administration of an isolated endostatin protein. Endostatin may be administered to individuals for treatment or repression of the growth of tumors, or administered to endothelial cells to inhibit their proliferation.
    Type: Grant
    Filed: September 16, 1998
    Date of Patent: October 7, 2003
    Assignee: The Children's Medical Center Corporation
    Inventors: Michael S. O'Reilly, M. Judah Folkman
  • Patent number: 6607724
    Abstract: The invention provides for methods of reducing or inhibiting angiogenesis, tumor growth and endothelial cell proliferation by the administration of compositions containing fragments, conformations, biological equivalent, or derivatives of antithrombin III. The invention also provides for pharmaceutical compositions comprising a fragment, conformation, biological equivalent, or derivative of antithrombin III and methods of identifying novel inhibitors of tumor growth, endothelial cell proliferation, and/or angiogenesis. The invention also relates to compositions and methods for altering angiogenesis in a mammal, as well as to methods of treatment for disorders associated with angiogenesis (e.g., cancer).
    Type: Grant
    Filed: October 8, 1999
    Date of Patent: August 19, 2003
    Assignee: Children's Hospital
    Inventors: Michael S. O'Reilly, M. Judah Folkman, Steven Pirie-Shepherd